Lisa M. Noguchi

TL;DR: Investigation of the safety and pharmacokinetics of seven days of TFV 1% vaginal gel in term and near‐term pregnancy found it to reduce incident HIV‐1 and herpes simplex virus 2 infection.

TL;DR: The Journal of Midwifery & Women's Health as mentioned in this paper has dedicated a special issue to women's health and midwife practice in global settings, and the articles in this special issue describe practice and interventions occurring globally.

TL;DR: Tenofovir use was well-tolerated and detected at low levels in maternal serum, milk, and infant serum but demonstrated no anti-HIV activity in milk.

TL;DR: An effective, efficient, and novel method to prospectively collect perinatal safety data concurrent with on-going parent clinical trials is described, feasible to establish and implement a prospective, multinational HIV chemoprophylaxis pregnancy registry that will generate pregnancy exposure data in a robust fashion.

TL;DR: This internationally themed issue would be remiss if it failed to comment on the global shortage of health workers such as nurses and midwives and its impact on maternal and child health outcomes in less developed countries.